| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/26/2009 | US20090053285 Medicament Carrier Composition and Method Of Forming A Film Therefrom |
| 02/26/2009 | US20090053283 such as vulvodynia via comprising administering polyarginine; for treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing agents |
| 02/26/2009 | US20090053273 Topical medication garment and system and method for providing topical medication |
| 02/26/2009 | US20090053263 Inhibitors of Enveloped Virus Infectivity |
| 02/26/2009 | US20090053255 Anti-arthropod vector vaccines, methods of selecting and uses thereof |
| 02/26/2009 | US20090053249 Specific Inhibition of Autoimmunity and Diseases Associated With Autoantigens |
| 02/26/2009 | US20090053245 Pharmacokinetics and Efficacy of Anti-Angiogenic Drugs and Drugs Treating Diseases of the Blood |
| 02/26/2009 | US20090053238 Stabilized High Concentration Anti-Integrin alphavbeta3 Antibody Formulations |
| 02/26/2009 | US20090053236 USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| 02/26/2009 | US20090053234 Methods of Preventing or Treating Inflammatory or Autoimmune Disorders by Administering Integrin ALPHAVBETA3 Antogonists in Combination with other Prophylactic or Therapeutic Agents |
| 02/26/2009 | US20090053232 Modulation of synaptogenesis |
| 02/26/2009 | US20090053226 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 02/26/2009 | US20090053222 Inhibitors of CD200 such as antibodies or antisense agents for treating cancer, tumor, leukemia |
| 02/26/2009 | US20090053216 Using endothelial growth factor specific monoclonal antibody for treatment and prevention of non-hodgkins lymphoma; immunotherapy |
| 02/26/2009 | US20090053209 Blockade of Pin1 Prevents Cytokine Production by Activated Immune Cells |
| 02/26/2009 | US20090053206 Novel synthetic agonists of tlr9 |
| 02/26/2009 | US20090053205 Stabilized immune modulatory rna (simra) compounds |
| 02/26/2009 | US20090053203 Chimeric metal binding protein for use in prevention and treatment of cancer, diabetes, obesity, cardiovascular, metabolic, neurodegenerative, gastrointestinal, autoimmune, rheumatological and infectious diseases; drug delivery |
| 02/26/2009 | US20090053198 Cytokine Induction of Selectin Ligands on Cells |
| 02/26/2009 | US20090053196 Chn-1/Chip-Antagonists For The Treatment Of Muscular Diseases |
| 02/26/2009 | US20090053192 Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| 02/26/2009 | US20090053191 Phospholipases, nucleic acids encoding them and methods for making and using them |
| 02/26/2009 | US20090053188 Method of preventing reduced feed intake in animals and treatment of disease conditions |
| 02/26/2009 | US20090053186 Therapy for primary and metastatic cancers |
| 02/26/2009 | US20090053185 Coagulation factor x polypeptides with modified activation properties |
| 02/26/2009 | US20090053184 Compositions comprising t cell receptors and methods of use thereof |
| 02/26/2009 | US20090053175 Substitute pyrrolidine derivatives |
| 02/26/2009 | US20090053172 Heterocyclic compounds as ccr5 antagonists |
| 02/26/2009 | US20090053171 Treatment of cellular proliferative disorders |
| 02/26/2009 | US20090053169 Oligonucleotide Core Carrier Compositions for Delivery of Nucleic Acid-Containing Therapeutic Agents, Methods of Making and Using the Same |
| 02/26/2009 | US20090053168 Such as multiple myeloma using an adenosine A2A receptor agonist e.g., SCH 58261, IB-MECA (CF 101), Cl-IBMECA, CGS-21680, Regadenoson, apadenoson, binodenoson, BVT-115959, and UK-432097 |
| 02/26/2009 | US20090053165 Method for Treating Damaged Hair |
| 02/26/2009 | US20090053163 Warming and nonirritating lubricant compositions and method of comparing irritation |
| 02/26/2009 | US20090053162 Bisphosphonate Formulation |
| 02/26/2009 | US20090053154 Mixtures of ethylhexyl p-methoxycinnamate and ethylhexyl salicylate |
| 02/26/2009 | US20090053152 Skin cosmetic |
| 02/26/2009 | US20090053149 nonionic surfactant such as Tyloxapol in a sterile aqueous solution of an antimicrobial such as an antibiotic; phosphatide-free; aerosol drug delivery to lungs |
| 02/26/2009 | US20090053148 Toll like receptor modulators |
| 02/26/2009 | US20090053146 Metronidazole-based dermatological foams and emulsions for the preparation thereof |
| 02/26/2009 | US20090053145 Anti-viral compositions and methods of use in cattle |
| 02/26/2009 | US20090053143 Liquid inhalation formulations of dehydroepiandrosterone derivatives |
| 02/26/2009 | US20090053138 Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics |
| 02/26/2009 | US20090053137 Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof |
| 02/26/2009 | US20090053136 Therapeutic immunoglobulin specific for lymphocyte adhesion protein for killing and/or inhibiting growth of cancer cells |
| 02/26/2009 | US20090049935 Stabilized milnacipran formulation |
| 02/26/2009 | DE102007040243A1 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen 17beta-dehydrogenase type 1 Hydroxysteriod inhibitors for the treatment of hormone-dependent diseases |
| 02/26/2009 | DE102007040000A1 Zwitterionische Verbindungen und deren Verwendung Zwitterionic compounds and their use |
| 02/26/2009 | DE102007039559A1 Piperazinpolyphosphat, Verfahren zu seiner Herstellung und seine Verwendung Piperazine, process for its preparation and its use |
| 02/26/2009 | DE102007039229A1 Wasser- und wirkstoffhaltiges Gel Water and gel containing active ingredients |
| 02/26/2009 | CA2734710A1 Pyrimidine and pyridine derivatives as posh and posh-ap inhibitors |
| 02/26/2009 | CA2707521A1 Imidazopyrazine compounds |
| 02/26/2009 | CA2701606A1 Antifungal agents |
| 02/26/2009 | CA2700463A1 Use of eif-5a1 sirna to protect islets cells from apoptosis and to preserve their functionality |
| 02/26/2009 | CA2698205A1 New use 938 |
| 02/26/2009 | CA2697328A1 Antifungal composition |
| 02/26/2009 | CA2697325A1 Pyrrolidine aryl-ether as nk3 receptor antagonists |
| 02/26/2009 | CA2697284A1 Therapeutic quinoline and naphthalene derivatives |
| 02/26/2009 | CA2697261A1 Treatment of lung cancer |
| 02/26/2009 | CA2697254A1 Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors |
| 02/26/2009 | CA2697246A1 Indolopyridines as inhibitors of the kinesin spindle protein (eg5) |
| 02/26/2009 | CA2697160A1 Stabilized therapeutic compositions and formulations |
| 02/26/2009 | CA2697150A1 Methods and compositions for controlling the bioavailability of poorly soluble drugs |
| 02/26/2009 | CA2697100A1 Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| 02/26/2009 | CA2697093A1 Use of carbon nanotube for drug delivery |
| 02/26/2009 | CA2697081A1 5-(4-(haloalkoxy)phenyl)pyrimidine-2-amine compounds and compositions as kinase inhibitors |
| 02/26/2009 | CA2697079A1 A method of extending the dose range of vitamin d compounds |
| 02/26/2009 | CA2697057A1 Therapy for complications of diabetes |
| 02/26/2009 | CA2697044A1 Liposome formulations of boronic acid compounds |
| 02/26/2009 | CA2697043A1 Methods and compositions for treatment or prevention of radiation-induced fibrosis |
| 02/26/2009 | CA2697042A1 Liposome compositions for in vivo administration of boronic acid compounds |
| 02/26/2009 | CA2696793A1 Novel preparation for external use |
| 02/26/2009 | CA2696753A1 Antiinfective flavononol compounds and methods of use thereof |
| 02/26/2009 | CA2696693A1 Azoloraine derivatives, method for the production thereof, pharmaceuticals containing these compounds, and the use thereof |
| 02/26/2009 | CA2696689A1 Renin inhibitors |
| 02/26/2009 | CA2696684A1 Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
| 02/26/2009 | CA2696680A1 1,4-diaza-bicycl0(3.2.2)n0nyl pyrimidinyl derivatives useful as nicotinic acetylcholine- receptor ligands |
| 02/26/2009 | CA2696632A1 High concentration local anesthetic formulations |
| 02/26/2009 | CA2696631A1 Heterocycles as potassium channel modulators |
| 02/26/2009 | CA2696591A1 Cdh3 peptide and medicinal agent comprising the same |
| 02/26/2009 | CA2696582A1 Use of tranilast and derivatives thereof for the therapy of neurological conditions |
| 02/26/2009 | CA2696579A1 Purine derivatives for use in the treatment of fab-related diseases |
| 02/26/2009 | CA2696523A1 Novel application of topical anesthetics for modulation of neurogenic tremor |
| 02/26/2009 | CA2696473A1 Small molecule inhibitors of lck sh2 domain binding |
| 02/26/2009 | CA2696472A1 6-thioxopyridazine derivatives |
| 02/26/2009 | CA2696211A1 Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 02/26/2009 | CA2696200A1 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders |
| 02/26/2009 | CA2696197A1 Pyridoneamide derivatives as focal adhesion kinase (fak) inhibitors and their use for the treatment of cancer |
| 02/26/2009 | CA2695511A1 4-pyrimidinesulfamide derivative |
| 02/26/2009 | CA2695509A1 Pyridine derivatives as s1p1/edg1 receptor modulators |
| 02/26/2009 | CA2695452A1 Hdac inhibitors |
| 02/26/2009 | CA2695434A1 Chemical compounds 979 |
| 02/26/2009 | CA2694919A1 Isoxazoline compositions and their use as antiparasitics |
| 02/26/2009 | CA2694604A1 N-benzyl, n' -arylcarbonylpiperazine derivatives as lxr modulators |
| 02/26/2009 | CA2694380A1 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl -propyl)-6,7-dihydro -1h- pyrrol[3,2-c]pyridine-4(5h)-one compounds and use as protein kinase inhibitors |
| 02/26/2009 | CA2694059A1 Novel method for producing dry hydrodispersible pharmaceutical forms |
| 02/26/2009 | CA2693846A1 A memory influencing protein |
| 02/26/2009 | CA2693152A1 Antitumour combinations containing a vegf inhibiting agent and irinotecan |
| 02/26/2009 | CA2691600A1 Hyaluronic acid injectable gel for treating joint degeneration |
| 02/26/2009 | CA2691450A1 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy |
| 02/26/2009 | CA2691368A1 Method for activating regulatory t-cells |